AGM - Revised Form of Proxy
Halma plc
Annual General Meeting 2025 (AGM) - Revised Form of Proxy
Following the publication and posting of the Notice of AGM of the Company to be held on 24 July 2025, together with a Form of Proxy, it has come to the Company's attention that the Form of Proxy contains a minor typographical error in relation to resolution 5. For the avoidance of doubt, the resolutions set out in the 2025 Notice of AGM are correct and the typographical error in the Form of Proxy does not affect the validity of the resolutions.
A Form of Proxy which has been submitted, or which is submitted prior to the proxy voting deadline of 12.30pm on 22 July 2025, will be treated as valid, notwithstanding the typographical error. As such, shareholders who have already returned their Form of Proxy do not need to take any action. A revised Form of Proxy is available on the Company's website at https://www.halma.com/investors/shareholder-information/agm-information. Shareholders who have not yet returned a Form of Proxy, or who wish to amend their original submission, may use the revised Form of Proxy, if preferred.
The revised Form of Proxy has also been submitted to the National Storage Mechanism and will shortly be available for inspection at https://data.fca.org.uk/#/nsm/nationalstoragemechanism.
|
For further information, please contact: |
|
|
|
|
|
Mark Jenkins Company Secretary, Halma plc Tel: +44 (0)1494 721111 |
|
NOTE TO EDITORS
Halma is a global group of life-saving technology companies, focused on growing a safer, cleaner, healthier future for everyone, every day. Its purpose defines the three market areas where it operates:
|
· Safety |
Protecting people, assets and infrastructure in commercial, industrial and public spaces. Reducing safety risks in hazardous situations, increasing efficiency and helping to create a more sustainable future.
|
|
· Environmental & Analysis |
Monitoring and protecting the environment, and ensuring the quality and availability of life‑critical resources. Creating solutions used in materials analysis and optoelectronic applications.
|
|
· Healthcare
|
Improving the care delivered by healthcare providers, and enhancing the quality of patients' lives, through contributing to the discovery and development of new cures, the diagnosis and treatment of patient conditions, and data analysis. |
Halma employs over 9,000 people in more than 20 countries, with major operations in the UK, Mainland Europe, the USA and Asia Pacific. Halma is listed on the London Stock Exchange (LON: HLMA) and is a constituent of the FTSE 100 index.
Halma has been named one of Britain's Most Admired Companies for the past six years.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Latest directors dealings
- 28 minutes ago Zotefoams
- 1 hour ago Antofagasta
- 1 hour ago United Utilities Group
- 2 hours ago Morgan Sindall Group
- 4 hours ago River Global Plc